We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Polymer Implant Vaccine Successful in Mouse Cancer Model

By LabMedica International staff writers
Posted on 02 Feb 2009
A new type of vaccine based on implantation of an infection-mimicking polymer with potential application against cancer as well as against infectious and autoimmune has been successfully tested in a mouse cancer model.

Investigators at Harvard University (Cambridge, MA, USA) have based their presumptive vaccine on small plastic disks (eight millimeters in diameter) that were impregnated with cytokines and specific tumor antigens before being inserted into tumor-bearing mice.

The polymer vaccine was designed so that dendritic cells would be attracted by the cytokines to the porous interior of the disk. More...
The immune cells would then interact with the tumor antigens that coat the polymer. Finally, the dendritic cells would spread to nearby lymph nodes where they would trigger a general immune response against cancer cells bearing the tumor antigens.

The investigators reported in the January 11, 2009, online edition of the journal Nature Materials that the specific and protective antitumor immunity generated by the polymer resulted in 90% survival of mice that otherwise would have died from cancer within 25 days.

"Our immune systems work by recognizing and attacking foreign invaders, allowing most cancer cells - which originate inside the body - to escape detection," explained senior author Dr. David J. Mooney, professor of bioengineering in Harvard University. "This technique, which redirects the immune system from inside the body, appears to be easier and more effective than other approaches to cancer vaccination."

"Much as an immune response to a bacterium or virus generates long-term resistance to that particular strain, we anticipate our materials will generate permanent and body-wide resistance against cancerous cells, providing durable protection against relapse," said Dr. Mooney. "This study demonstrated a powerful new application for polymeric biomaterials that may potentially be used to treat a variety of diseases by programming or reprogramming host cells. The system may be applicable to other situations in which it is desirable to promote a destructive immune response (for example, eradicate infectious diseases) or to promote tolerance (for example, subvert autoimmune disease)."

Related Links:
Harvard University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.